| 產(chǎn)品編號 | bs-55208R |
| 英文名稱 | [KO驗證抗體] STAT3 Rabbit pAb |
| 中文名稱 | 信號轉(zhuǎn)導(dǎo)和轉(zhuǎn)錄激活因子3抗體 |
| 別 名 | 1110034C02Rik; Acute Phase Response Factor; APRF; AW109958; DNA binding protein APRF; FLJ20882; HIES; MGC128731; MGC16063; MGC93551; Signal transducer and activator of transcription 3(acute-phase response factor); Signal transducer and activator of transcription 3; Signal Transductor and Activator of Transcription 3; STAT 3; Transcription factor; STAT3_HUMAN. |
 |
Specific References (6) | bs-55208R has been referenced in 6 publications.
[IF=6.63] Guo, Zhi-chen. et al. Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment. CANCER IMMUNOL IMMUN. 2022 Dec;:1-17 WB ; Mouse.
[IF=6.208] Yanan Hao. et al. Alginate Oligosaccharides Repair Liver Injury by Improving Anti-Inflammatory Capacity in a Busulfan-Induced Mouse Model. INT J MOL SCI. 2023 Jan;24(4):3097 WB,IF ; Mouse.
[IF=5.988] Yeke Wu. et al. Aconiti lateralis radix praeparata total alkaloids exert anti-RA effects by regulating NF-κB and JAK/STAT signaling pathways and promoting apoptosis.. FRONT PHARMACOL. 2022 Sep;13:980229-980229 WB ; Human.
[IF=4.101] Haixiang Ding. et al. Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway. Int J Mol Med. 2022 Feb;49(2):1-11 WB ; Human.
[IF=3.269] Leiming Sun. et al. Isoliquiritigenin attenuates acute renal injury through suppressing oxidative stress, fibrosis and JAK2/STAT3 pathway in streptozotocin-induced diabetic rats. Bioengineered. 2021;12(2):11188-11200 WB ; Rat.
[IF=2.605] Wang Yaxin. et al. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation. BMC PHARMACOL TOXICO. 2022 Dec;23(1):1-13 WB ; Human.
|
| 研究領(lǐng)域 | 腫瘤 細胞生物 發(fā)育生物學(xué) 細胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號 | |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 88 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human STAT3: 640-770 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The protein encoded by this gene is a member of the STAT protein family. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated through phosphorylation in response to various cytokines and growth factors including IFNs, EGF, IL5, IL6, HGF, LIF and BMP2. This protein mediates the expression of a variety of genes in response to cell stimuli, and thus plays a key role in many cellular processes such as cell growth and apoptosis. The small GTPase Rac1 has been shown to bind and regulate the activity of this protein. PIAS3 protein is a specific inhibitor of this protein. Mutations in this gene are associated with infantile-onset multisystem autoimmune disease and hyper-immunoglobulin E syndrome. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Sep 2015] Subunit: Forms a homodimer or a heterodimer with a related family member (at least STAT1). Interacts with IL31RA, NCOA1, PELP1, SIPAR, SOCS7, STATIP1 and TMF1. Interacts with HCV core protein. Interacts with IL23R in presence of IL23. Interacts (via SH2 domain) with NLK. Interacts with ARL2BP; the interaction is enhanced by LIF and JAK1 expression (By similarity). Interacts with KPNA4 and KPNA5; KPNA4 may be the primary mediator of nuclear import (By similarity). Interacts with CAV2; the interaction is increased on insulin-induced tyrosine phosphorylation of CAV2 and leads to STAT3 activation (By similarity). Interacts with ARL2BP; interaction is enhanced with ARL2. Interacts with NEK6 (By similarity). Binds to CDK9 when activated and nuclear. Interacts with BMX. Interacts with ZIPK/DAPK3. Interacts with PIAS3; the interaction occurs on stimulation by IL6, CNTF or OSM and inhibits the DNA binding activity of STAT3. In prostate cancer cells, interacts with STAT3 and promotes DNA binding activity of STAT3. Interacts with STMN3, antagonizing its microtubule-destabilizing activity. Subcellular Location: Cytoplasm. Nucleus. Note=Shuttles between the nucleus and the cytoplasm. Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4. Constitutive nuclear presence is independent of tyrosine phosphorylation. Predominantly present in the cytoplasm without stimuli. Upon leukemia inhibitory factor (LIF) stimulation, accumulates in the nucleus. The complex composed of BART and ARL2 plays an important role in the nuclear translocation and retention of STAT3. Identified in a complex with LYN and PAG1. Tissue Specificity: Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Similarity: Belongs to the transcription factor STAT family. Contains 1 SH2 domain. SWISS: P40763 Gene ID: 6774 Database links: Entrez Gene: 6774 Human Entrez Gene: 20848 Mouse Omim: 102582 Human SwissProt: P40763 Human SwissProt: P42227 Mouse Unigene: 463059 Human
Stat3在細胞分化、增殖、凋亡等方面有著重要生理作用。有學(xué)者認為：STAT-3對腫瘤有一定的抑制作用，由于其與腫瘤的關(guān)系較為密切，越來越受到人們的重視。 |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with STAT3 polyclonal antibody, unconjugated (bs-55208R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
